

August 26, 2025

To,
**Department of Corporate Relationship
BSE Ltd.**
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001.
Scrip Code: 539177

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051
NSE Symbol – AIIL

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”)

With reference to the above subject, we wish to inform you that today the Company has entered into the following binding agreements:

- (a) Share Subscription cum Purchase Agreement dated August 25, 2025 (“SSPA”) with *inter alia* Rivaara Labs Private Limited (“**Rivaara Labs**”) and Mr. Siddharth Bharat Daftary, recording the terms and conditions for *inter alia*:
- (i) Rivaara Labs issuing and offering and the Company subscribing to 3,60,00,000 (Three Crore and Sixty Lakhs) cumulative compulsorily convertible participating preference shares of Rivaara Labs (“CCPS”); and
 - (ii) the Company purchasing from certain existing shareholders of Rivaara Labs, and certain existing shareholders of Rivaara Labs selling to the Company:
 - 1,58,42,000 (One Crore Fifty-Eight Lakh Forty-Two Thousand) equity shares of Rivaara Labs, and
 - 4,09,88,011 (Four Crore Nine Lakh Eighty-Eight Thousand and Eleven) CCPS,

in aggregate, constituting 35.09% (Thirty Five point Zero Nine Per Cent) of the total voting rights of Rivaara Labs; and

The consummation of the transactions contemplated the SSPA is subject to satisfactory fulfilment of certain conditions precedent recorded in the SSPA, including receipt of the necessary corporate authorizations. Upon consummation of the transactions contemplated under the SSPA, the Company shall be entitled to exercise 35.09% (Thirty-Five point Zero Nine Per Cent) of the total voting rights of Rivaara Labs.



AUTHUM INVESTMENT & INFRASTRUCTURE LTD.

CIN : L51109MH1982PLC319008

Further, the details required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in **Annexure A**.

Kindly take the same on your records.

Thank you,
For **Authum Investment & Infrastructure Limited**

Amit Dangi
Whole Time Director
DIN: 06527044

Registered Office : 707, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai - 400 021.

Ph.: (022) 6747 2117 ♦ **E-mail:** info@authum.com ♦ **Website :** www.authum.com

Corporate Office: The Ruby, 11th Floor, North- West Wing, Plot No. 29, Senapati Bapat Marg, Dadar (West), Mumbai – 400 028.

T +91 22 6838 8100 ♦ **Customer Service:** **T** +91 22 4741 5800 ♦ **E-mail:** customercare@authum.com

Annexure A

Disclosure of information pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Name of the target entity, details in brief such as size, turnover etc.;	<p>Rivaara Labs Private Limited, a company existing under the laws of India, having Corporate Identification Number (CIN) U85300MH2019PTC331867 and having its registered office at 17th Floor, Hoechst House, Nariman Point, Mumbai, Maharashtra, India, 400 021 ("Rivaara Labs").</p> <p>Net Worth of Rivaara Labs (as of March 31, 2025): Rs. (3482.93) lakhs</p> <p>Turnover of Rivaara Labs (as of March 31, 2025): Rs. 2552.69 lakhs</p>
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired. If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No
Industry to which the entity being acquired belongs;	<p>Rivaara Labs is engaged in the business of <i>inter alia</i>:</p> <ul style="list-style-type: none"> (i) Establishing and operating diagnostic service centres including pathology, imaging, PCR testing and genomic sequencing; (ii) Distribution, marketing, manufacturing point of care diagnostic kits and equipment based on molecular biology in India; (iii) RT-PCR (Reverse Transcription Polymerase Chain Reaction) related diagnostic services, such as development, manufacture, distribution, and sale of test kits, reagents, enzymes, and related consumables used for the detection, quantification, or monitoring of infectious diseases in humans, as well as the provision of clinical laboratory testing, sample collection, and diagnostic reporting services associated with such RT-PCR tests; and (iv) Rendering of digital healthcare products and / or services related to diagnostics

Registered Office : 707, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai - 400 021.

Ph.: (022) 6747 2117 ♦ **E-mail:** info@authum.com ♦ **Website :** www.authum.com

Corporate Office: The Ruby, 11th Floor, North- West Wing, Plot No. 29, Senapati Bapat Marg, Dadar (West), Mumbai – 400 028.

T +91 22 6838 8100 ♦ **Customer Service:** T +91 22 4741 5800 ♦ **E-mail:** customercare@authum.com

Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	This acquisition aligns with our long-term strategy of diversifying our portfolio while investing in sectors that demonstrate both stability and growth potential. Our intention is to nurture and expand this business, maximizing value creation for all stakeholders and ensuring a sustainable, profitable future for the Company.
Brief details of any governmental or regulatory approvals required for the acquisition;	No government or regulatory approvals are contemplated to be required for the acquisition. However, consummation of the transaction is subject to satisfactory fulfilment of certain conditions precedent, including board and shareholder approvals of Rivaara Labs.
Indicative time period for completion of the acquisition;	Subject to completion of conditions precedent as detailed in the SSPA, the acquisition contemplated under the SSPA is expected to be completed by September 30, 2025.
Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash consideration
Cost of acquisition and/or the price at which the shares are acquired;	<p>Total cost of acquisition is Rs. 36,56,83,001 (Indian Rupees Thirty Six Crore Fifty Six Lakh Eighty Three Thousand and One), having the following segregation:</p> <ol style="list-style-type: none"> 1. Primary Infusion of Rs. 36,00,00,000 (Indian Rupees Thirty Six Crores) to subscribe to 3,60,00,000 (Three Crore Sixty Lakhs) cumulative compulsorily convertible participating preference shares of Rivaara Labs, having face value of Rs. 10 (Indian Rupees Ten) each ("CCPS"); 2. Purchase Consideration of Rs. 56,83,001 (Indian Rupees Fifty-Six Lakh Eighty-Three Thousand and One) for purchase of: <ul style="list-style-type: none"> - 1,58,42,000 (One Crore Fifty-Eight Lakh Forty-Two Thousand) equity shares, and - 4,09,88,011 (Four Crore Nine Lakh Eighty-Eight Thousand and Eleven) CCPS.
Percentage of shareholding / control acquired and / or number of shares acquired;	Pursuant to the proposed transaction, the Company shall be holding (i) 7,69,88,011 (Seven Crore Sixty Nine Lakh Eighty Eight Thousand and Eleven) CCPS; and (ii) 1,58,42,000 (One Crore Fifty-Eight Lakh Forty-Two Thousand) equity shares of

Registered Office : 707, Raheja Centre, Free Press Journal Road, Nariman Point, Mumbai - 400 021.

Ph.: (022) 6747 2117 ♦ **E-mail:** info@authum.com ♦ **Website :** www.authum.com

Corporate Office: The Ruby, 11th Floor, North- West Wing, Plot No. 29, Senapati Bapat Marg, Dadar (West), Mumbai – 400 028.

T +91 22 6838 8100 ♦ **Customer Service:** **T** +91 22 4741 5800 ♦ **E-mail:** customercare@authum.com

	Rivaara Labs, in aggregate entitling the Company to exercise 35.09% (Thirty-Five point Zero Nine Per Cent) of the total voting rights of Rivaara Labs.
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>Rivaara Labs is engaged in the business of <i>inter alia</i>:</p> <ul style="list-style-type: none"> (i) Establishing and operating diagnostic service centres including pathology, imaging, PCR testing and genomic sequencing; (ii) Distribution, marketing, manufacturing point of care diagnostic kits and equipment based on molecular biology in India; (iii) RT-PCR (Reverse Transcription Polymerase Chain Reaction) related diagnostic services, such as development, manufacture, distribution, and sale of test kits, reagents, enzymes, and related consumables used for the detection, quantification, or monitoring of infectious diseases in humans, as well as the provision of clinical laboratory testing, sample collection, and diagnostic reporting services associated with such RT-PCR tests; and (iv) Rendering of digital healthcare products and / or services related to diagnostics <p>Date of Incorporation: 18th October, 2019</p> <p>Turnover of last 3 years:</p> <p>FY 22-23 : INR 2336.20 FY 23-24 : INR 2670.24 FY 24-25 : INR 2252.69</p> <p>Country in which Rivaara Labs has presence: India</p>